Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Abstract Background Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long ter...

全面介紹

書目詳細資料

發表在:	Respiratory Research
Main Authors:	Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias J. Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
格式:	Article
語言:	英语
出版:	BMC 2018-12-01
主題:	Pulmonary hypertension Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension Riociguat Soluble guanylate cyclase stimulator Right atrial area
在線閱讀:	http://link.springer.com/article/10.1186/s12931-018-0957-y